News | December 20, 2011

Boston Scientific’s Ion Stent Demonstrates Positive Outcomes in PERSEUS Trial

December 20, 2011 – Boston Scientific reported positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the Ion (Taxus Element) paclitaxel-eluting patinum chromium stent system versus prior-generation paclitaxel-eluting stents.  Results were presented today by PERSEUS clinical program principal investigators Louis Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Mich., and Dean Kereiakes, M.D., medical director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

"The PERSEUS trials build on the extensive TAXUS clinical program and extend the consistent outcomes seen with prior-generation paclitaxel stents to the platinum chromium Ion Stent platform," said Cannon.  "The excellent clinical results at two years confirm the Ion stent's safety and efficacy in workhorse lesions and suggest superior performance relative to bare-metal stents in small vessels.  In addition, I have found the new alloy and stent design to offer increased flexibility, visibility and deliverability."

PERSEUS Workhorse and Small Vessel Trials

Cannon presented results from the prospective, randomized pivotal PERSEUS Workhorse trial, which demonstrated comparable safety and efficacy at two years for the Ion Stent compared to the Boston Scientific Taxus Express stent in more than 1,200 patients with de novo workhorse lesions.  Both stents showed similar rates of composite measures for target lesion failure (TLF) and major adverse cardiac events (MACE).  Individual safety measures of cardiac death, myocardial infarction (MI) and stent thrombosis remained low at two-year follow-up, demonstrating durable outcomes and successful transfer of the paclitaxel drug and polymer technology to the platinum chromium thin-strut platform.

Results were also presented from the PERSEUS Small Vessel trial, which compared the Ion Stent in 223 patients with small vessels (greater than or equal to 2.25 to <2.75 mm diameter) to a matched historical control group of 125 patients treated with the Express bare-metal stent.  The Ion Stent demonstrated similar safety and superior performance at two years compared to the Express Stent with significantly lower propensity-adjusted rates of target lesion revascularization (TLR, 7.1 percent vs. 20.8 percent, p=0.009) in patients with lesions in small vessels.

PERSEUS-ATLAS Trial Comparison

In an analysis of the PERSEUS and TAXUS ATLAS clinical trial programs, Kereiakes presented results that demonstrated safety outcomes favoring the Ion (Taxus Element) stent compared to the Boston Scientific second-generation Taxus Liberte paclitaxel-eluting stent.  The study compared pooled patient-level data from 2,298 patients enrolled in the PERSEUS (Ion stent) and TAXUS ATLAS (Taxus Liberte stent) trials.  Propensity-matched results revealed that the Ion Stent achieved significantly lower rates of MACE at two years (11.5 percent vs. 15.1 percent, p=0.04) and a numerically lower rate of TLF (8.2 percent vs. 11.0 percent, p=0.07), driven mainly by a reduction in MI (2.5 percent vs. 4.9 percent, p=0.02).

"The significantly lower rates of MACE and MI in this propensity-matched analysis demonstrate that the platinum chromium alloy, new stent design and thinner struts of the Ion Stent may favorably influence clinical outcomes," said Kereiakes.  "The PERSEUS trial results build confidence in this next-generation platinum chromium alloy, which, in my experience, offers noticeable performance improvements including enhanced flexibility, visibility and radial strength."

The Ion stent system features an innovative platinum chromium alloy and improved stent design to offer greater radial strength, enhanced deliverability and exceptional visibility.  The thin-strut stent is designed for improved conformability, minimal recoil, and uniform lesion coverage and drug distribution.  The advanced low-profile delivery system facilitates precise stent delivery across challenging lesions.  

The Ion stent system received U.S. Food and Drug Administration (FDA) approval in April 2011.

For more information: www.bostonscientific.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init